We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
-4.66%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$12.5B
AUM Growth
-$1.66B
Cap. Flow
-$1.45B
Cap. Flow %
-11.6%
Top 10 Hldgs %
32.88%
Holding
1,206
New
194
Increased
593
Reduced
261
Closed
41

Sector Composition

Rank Sector Weight
1 Real Estate 73.13%
2 Industrials 4.58%
3 Technology 4.24%
4 Financials 3.1%
5 Healthcare 2.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EGRX
1076
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4K ﹤0.01%
+82
New +$4.77K
KDNY
1077
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4K ﹤0.01%
+85
New +$3.11K
JNCE
1078
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$4K ﹤0.01%
+178
New +$3.95K
CCXI
1079
DELISTED
ChemoCentryx, Inc.
CCXI
$4K ﹤0.01%
+269
New +$2.77K
AMAG
1080
DELISTED
AMAG Pharmaceuticals
AMAG
$4K ﹤0.01%
+195
New +$3.3K
DOVA
1081
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$4K ﹤0.01%
+142
New +$4.25K
ACRS icon
1082
Aclaris Therapeutics
ACRS
$730M
$3K ﹤0.01%
+170
New +$3.6K
ARWR icon
1083
Arrowhead Research
ARWR
$12.1B
$3K ﹤0.01%
+477
New +$2.94K
BCRX icon
1084
BioCryst Pharmaceuticals
BCRX
$2.37B
$3K ﹤0.01%
+544
New +$2.79K
CERS icon
1085
Cerus
CERS
$587M
$3K ﹤0.01%
+630
New +$2.87K
CBIO
1086
Crescent Biopharma
CBIO
$602M
$3K ﹤0.01%
+2
New +$4.16K
KURA icon
1087
Kura Oncology
KURA
$922M
$3K ﹤0.01%
+167
New +$3.25K
OMER icon
1088
Omeros
OMER
$709M
$3K ﹤0.01%
+265
New +$3.72K
RIGL icon
1089
Rigel Pharmaceuticals
RIGL
$680M
$3K ﹤0.01%
+81
New +$3.24K
VYGR icon
1090
Voyager Therapeutics
VYGR
$187M
$3K ﹤0.01%
+178
New +$3.85K
CNCE
1091
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$3K ﹤0.01%
+126
New +$2.8K
ADMS
1092
DELISTED
Adamas Pharmaceuticals
ADMS
$3K ﹤0.01%
+142
New +$4.48K
FPRX
1093
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3K ﹤0.01%
+160
New +$3.12K
PGNX
1094
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$3K ﹤0.01%
+388
New +$2.58K
ACHN
1095
DELISTED
Achillion Pharmaceuticals
ACHN
$3K ﹤0.01%
+762
New +$2.49K
AKAO
1096
DELISTED
Achaogen Inc
AKAO
$3K ﹤0.01%
+234
New +$2.65K
PDLI
1097
DELISTED
PDL BioPharma, Inc.
PDLI
$3K ﹤0.01%
+853
New +$2.33K
ABUS icon
1098
Arbutus Biopharma
ABUS
$865M
$2K ﹤0.01%
+304
New +$1.61K
AKBA icon
1099
Akebia Therapeutics
AKBA
$327M
$2K ﹤0.01%
+261
New +$3.65K
ASRT
1100
DELISTED
Assertio
ASRT
$2K ﹤0.01%
+6
New +$2.63K

Similar funds

Daiwa Securities Group's Q1 2018 Portfolio in Review

As of Q1 2018, Daiwa Securities Group held 1,206 positions worth $12.5B, down 12% from $14.1B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Daiwa Securities Group withdrew a net $1.45B in Q1 2018, closing 41 positions and reducing 261 holdings. Its most notable exit was Anthem, Inc., an estimated $25.2M position sold in full.

By sector, the portfolio is most concentrated in Real Estate at 73% of assets, down from 77% a quarter earlier, followed by Industrials and Technology.

Against the trend, Daiwa Securities Group opened a new position in Supernus Pharmaceuticals worth $3.16M.

  • Daiwa Securities Group's largest Q1 2018 buy was Supernus Pharmaceuticals: 68,983 shares worth $3.16M.
  • Daiwa Securities Group added most to Boston Properties in Q1 2018, an estimated $165M increase.
  • Daiwa Securities Group's biggest Q1 2018 reduction was Simon Property Group, cutting an estimated $275M.
  • Daiwa Securities Group fully exited Anthem, Inc. in Q1 2018, selling an estimated $25.2M.
  • Daiwa Securities Group's ten largest holdings make up 33% of its $12.5B portfolio in Q1 2018.
  • Daiwa Securities Group opened 194 new positions and closed 41 in Q1 2018.
  • Daiwa Securities Group's portfolio value fell 12% quarter-over-quarter to $12.5B.

Based on Daiwa Securities Group's 13F filing for Q1 2018, filed 2 May 2018.